Interventional Cardiology Market: By Type (Stents (Drug-Eluting Stents, Bare Metal Stents and Bioresorbable Vascular Scaffolds), Percutaneous Transluminal Coronary Angioplasty (PTCA) Catheters (Balloon Catheters and Guiding Catheters), Plaque Modification Devices, Coronary Guidewires, and Accessories), End-User (Hospitals, Cardiac Catheterization Laboratories, Ambulatory Surgical Centers, Others), Region (Americas, Europe, Asia-Pacific, Middle East & Africa)- Forecast to 2027
ID: MRFR/HC/7263-HCR | February 2021 | Region: Global | 113 Pages
Table of Contents
1. EXECUTIVE SUMMARY
1.1. Market Attractiveness Analysis
1.1.1. Global Interventional Cardiology Market, by Type
1.1.2. Global Interventional Cardiology Market, by End User
2. MARKET INTRODUCTION
2.1. Definition
2.2. Scope of the Study
2.2.1. Research Objective
2.2.2. Assumptions
2.2.3. Limitations
3. RESEARCH METHODOLOGY
3.1. Overview
3.2. Data Mining
3.3. Secondary Research
3.4. Primary Research
3.4.1. Breakdown of Primary Respondents
3.5. Forecasting Techniques
3.6. Research Methodology for Market Size Estimation
3.6.1. Bottom-Up Approach
3.6.2. Top-Down Approach
3.7. Data Triangulation
3.8. Validation
4. MARKET DYNAMICS
4.1. Overview
4.2. Drivers
4.3. Restraints
4.4. Opportunities
5. MARKET FACTOR ANALYSIS
5.1. Porter’s Five Forces Analysis
5.1.1. Bargaining Power of Suppliers
5.1.2. Bargaining Power of Buyers
5.1.3. Threat of New Entrants
5.1.4. Threat of Substitutes
5.1.5. Intensity of Rivalry
5.2. Value Chain Analysis
5.2.1. R&D and Designing
5.2.2. Manufacturing
5.2.3. Distribution and Sales
5.2.4. Post Sales Services
6. GLOBAL INTERVENTIONAL CARDIOLOGY MARKET, BY TYPE
6.1. Overview
6.2. Stents
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.2.1. Drug Eluting Stents
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.2.2. Bare Metal Stents
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.2.3. Bioresorbable Vascular Scaffolds
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.3. PTCA Catheters
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.3.1. Balloon Catheters
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.3.2. Guiding Catheters
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.4. Plaque Modification Devices
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.5. Coronary Guidewires
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.6. Accessories
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7. GLOBAL INTERVENTIONAL CARDIOLOGY MARKET, BY END USER
7.1. Overview
7.2. Hospitals
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.3. Cardiac Catheterization Laboratories
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.4. Ambulatory Surgical Centers
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.5. Others
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
8. GLOBAL INTERVENTIONAL CARDIOLOGY MARKET, BY REGION
8.1. Overview
8.2. Americas
8.2.1. North America
8.2.1.1. US
8.2.1.2. Canada
8.2.2. Latin America
8.3. Europe
8.3.1. Western Europe
8.3.1.1. Germany
8.3.1.2. France
8.3.1.3. Italy
8.3.1.4. Spain
8.3.1.5. UK
8.3.1.6. Rest of Western Europe
8.3.2. Eastern Europe
8.4. Asia-Pacific
8.4.1. Japan
8.4.2. China
8.4.3. India
8.4.4. Australia
8.4.5. South Korea
8.4.6. Rest of Asia-Pacific
8.5. Middle East & Africa
8.5.1. Middle East
8.5.2. Africa
9. COMPANY LANDSCAPE
9.1. Overview
9.2. Competitive Analysis
9.3. Company Share Analysis
9.4. Competitor Dashboard
9.5. Major Growth Strategy in the Global Interventional Cardiology Market
9.6. Competitive Benchmarking
9.7. Leading Player in terms of Number of Developments in the Global Interventional Cardiology Market
9.8. Key Developments & Growth Strategies
9.8.1. New Product Launch
9.8.2. Merger & Acquisition
9.8.3. Joint Ventures
9.9. Major Players Financial Matrix & Market Ratio
9.9.1. Sales & Operating Income 2020
9.9.2. Major Players R&D Expenditure 2020
9.9.3. Major Players Capital Market Ratio
10. COMPANY PROFILES
10.1. ABIOMED
10.1.1. Company Overview
10.1.2. Products/Services Offered
10.1.3. Financial Overview
10.1.4. Key Developments
10.1.5. SWOT Analysis
10.1.6. Key Strategies
10.2. Abbott
10.3. ACIST Medical Systems, Inc.
10.4. B. Braun Melsungen AG
10.5. BD
10.6. Biosense Webster, Inc
10.7. Biotronik SE & Co. KG
10.8. Boston Scientific Corporation
10.9. Cardinal Health
10.10. Cook Medical
10.11. Edwards Lifesciences Corporation
10.12. GE Healthcare
10.13. Koninklijke Philips N.V.
10.14. Life Vascular Devices Biotech S.L.
10.15. Medtronic
10.16. Merit Medical Systems, Inc
10.17. Terumo Corporation
10.18. W. L. Gore & Associates, Inc.
10.19. Others
11. APPENDIX
11.1. References
11.2. Related Reports
LIST OF TABLES
TABLE 1 GLOBAL INTERVENTIONAL CARDIOLOGY MARKET SYNOPSIS, 2020-2027
TABLE 2 GLOBAL INTERVENTIONAL CARDIOLOGY MARKET ESTIMATES & FORECAST, 2020-2027 (USD MILLION)
TABLE 3 GLOBAL INTERVENTIONAL CARDIOLOGY MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 4 GLOBAL INTERVENTIONAL CARDIOLOGY MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 5 GLOBAL INTERVENTIONAL CARDIOLOGY MARKET, BY REGION, 2020-2027 (USD MILLION)
TABLE 6 NORTH AMERICA: INTERVENTIONAL CARDIOLOGY MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 7 NORTH AMERICA: INTERVENTIONAL CARDIOLOGY MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 8 US: INTERVENTIONAL CARDIOLOGY MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 9 US: INTERVENTIONAL CARDIOLOGY MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 10 CANADA: INTERVENTIONAL CARDIOLOGY MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 11 CANADA: INTERVENTIONAL CARDIOLOGY MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 12 LATIN AMERICA: INTERVENTIONAL CARDIOLOGY MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 13 LATIN AMERICA: INTERVENTIONAL CARDIOLOGY MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 14 EUROPE: INTERVENTIONAL CARDIOLOGY MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 15 EUROPE: INTERVENTIONAL CARDIOLOGY MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 16 WESTERN EUROPE: INTERVENTIONAL CARDIOLOGY MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 17 WESTERN EUROPE: INTERVENTIONAL CARDIOLOGY MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 18 EASTERN EUROPE: INTERVENTIONAL CARDIOLOGY MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 19 EASTERN EUROPE: INTERVENTIONAL CARDIOLOGY MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 20 ASIA-PACIFIC: INTERVENTIONAL CARDIOLOGY MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 21 ASIA-PACIFIC: INTERVENTIONAL CARDIOLOGY MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 22 MIDDLE EAST & AFRICA: INTERVENTIONAL CARDIOLOGY MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 23 MIDDLE EAST & AFRICA: INTERVENTIONAL CARDIOLOGY MARKET, BY END USER, 2020-2027 (USD MILLION)
LIST OF FIGURES
FIGURE 1 RESEARCH PROCESS
FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL INTERVENTIONAL CARDIOLOGY MARKET
FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL INTERVENTIONAL CARDIOLOGY MARKET
FIGURE 4 GLOBAL INTERVENTIONAL CARDIOLOGY MARKET SHARE, BY TYPE, 2020 (%)
FIGURE 5 GLOBAL INTERVENTIONAL CARDIOLOGY MARKET SHARE, BY END USER, 2020 (%)
FIGURE 6 GLOBAL INTERVENTIONAL CARDIOLOGY MARKET SHARE, BY REGION, 2020 (%)
FIGURE 7 AMERICAS: INTERVENTIONAL CARDIOLOGY MARKET SHARE BY REGION, 2020 (%)
FIGURE 8 NORTH AMERICA: INTERVENTIONAL CARDIOLOGY MARKET SHARE, BY COUNTRY, 2020 (%)
FIGURE 9 EUROPE: INTERVENTIONAL CARDIOLOGY MARKET SHARE, BY REGION, 2020 (%)
FIGURE 10 WESTERN EUROPE: INTERVENTIONAL CARDIOLOGY MARKET SHARE, BY COUNTRY, 2020 (%)
FIGURE 11 ASIA-PACIFIC: INTERVENTIONAL CARDIOLOGY MARKET SHARE, BY COUNTRY, 2020 (%)
FIGURE 12 MIDDLE EAST & AFRICA: INTERVENTIONAL CARDIOLOGY MARKET SHARE, BY COUNTRY, 2020 (%)
FIGURE 13 GLOBAL INTERVENTIONAL CARDIOLOGY MARKET: COMPANY SHARE ANALYSIS, 2020 (%)
FIGURE 14 ABIOMED: KEY FINANCIALS
FIGURE 15 ABIOMED: SEGMENTAL REVENUE
FIGURE 16 ABIOMED: REGIONAL REVENUE
FIGURE 17 ABBOTT: KEY FINANCIALS
FIGURE 18 ABBOTT: SEGMENTAL REVENUE
FIGURE 19 ABBOTT: REGIONAL REVENUE
FIGURE 20 ACIST MEDICAL SYSTEMS, INC.: KEY FINANCIALS
FIGURE 21 ACIST MEDICAL SYSTEMS, INC.: SEGMENTAL REVENUE
FIGURE 22 ACIST MEDICAL SYSTEMS, INC.: REGIONAL REVENUE
FIGURE 23 B. BRAUN MELSUNGEN AG: KEY FINANCIALS
FIGURE 24 B. BRAUN MELSUNGEN AG: SEGMENTAL REVENUE
FIGURE 25 B. BRAUN MELSUNGEN AG: REGIONAL REVENUE
FIGURE 26 BD: KEY FINANCIALS
FIGURE 27 BD: SEGMENTAL REVENUE
FIGURE 28 BD: REGIONAL REVENUE
FIGURE 29 BIOSENSE WEBSTER, INC: KEY FINANCIALS
FIGURE 30 BIOSENSE WEBSTER, INC: SEGMENTAL REVENUE
FIGURE 31 BIOSENSE WEBSTER, INC: REGIONAL REVENUE
FIGURE 32 BIOTRONIK SE & CO. KG: KEY FINANCIALS
FIGURE 33 BIOTRONIK SE & CO. KG: SEGMENTAL REVENUE
FIGURE 34 BIOTRONIK SE & CO. KG: REGIONAL REVENUE
FIGURE 35 BOSTON SCIENTIFIC CORPORATION.: KEY FINANCIALS
FIGURE 36 BOSTON SCIENTIFIC CORPORATION.: SEGMENTAL REVENUE
FIGURE 37 BOSTON SCIENTIFIC CORPORATION.: REGIONAL REVENUE
FIGURE 38 CARDINAL HEALTH: KEY FINANCIALS
FIGURE 39 CARDINAL HEALTH: SEGMENTAL REVENUE
FIGURE 40 CARDINAL HEALTH: REGIONAL REVENUE
FIGURE 41 COOK MEDICAL: KEY FINANCIALS
FIGURE 42 COOK MEDICAL: SEGMENTAL REVENUE
FIGURE 43 COOK MEDICAL: REGIONAL REVENUE
FIGURE 44 EDWARDS LIFESCIENCES CORPORATION: KEY FINANCIALS
FIGURE 45 EDWARDS LIFESCIENCES CORPORATION: SEGMENTAL REVENUE
FIGURE 46 EDWARDS LIFESCIENCES CORPORATION: REGIONAL REVENUE
FIGURE 47 GE HEALTHCARE: KEY FINANCIALS
FIGURE 48 GE HEALTHCARE: SEGMENTAL REVENUE
FIGURE 49 GE HEALTHCARE: REGIONAL REVENUE
FIGURE 50 KONINKLIJKE PHILIPS N.V.: KEY FINANCIALS
FIGURE 51 KONINKLIJKE PHILIPS N.V.: SEGMENTAL REVENUE
FIGURE 52 KONINKLIJKE PHILIPS N.V.: REGIONAL REVENUE
FIGURE 53 LIFE VASCULAR DEVICES BIOTECH S.L.: KEY FINANCIALS
FIGURE 54 LIFE VASCULAR DEVICES BIOTECH S.L.: SEGMENTAL REVENUE
FIGURE 55 LIFE VASCULAR DEVICES BIOTECH S.L.: REGIONAL REVENUE
FIGURE 56 MEDTRONIC: KEY FINANCIALS
FIGURE 57 MEDTRONIC: SEGMENTAL REVENUE
FIGURE 58 MEDTRONIC: REGIONAL REVENUE
FIGURE 59 MERIT MEDICAL SYSTEMS, INC: KEY FINANCIALS
FIGURE 60 MERIT MEDICAL SYSTEMS, INC: SEGMENTAL REVENUE
FIGURE 61 MERIT MEDICAL SYSTEMS, INC: REGIONAL REVENUE
FIGURE 62 TERUMO CORPORATION: KEY FINANCIALS
FIGURE 63 TERUMO CORPORATION: SEGMENTAL REVENUE
FIGURE 64 TERUMO CORPORATION: REGIONAL REVENUE
FIGURE 65 W. L. GORE & ASSOCIATES, INC.: KEY FINANCIALS
FIGURE 66 W. L. GORE & ASSOCIATES, INC.: SEGMENTAL REVENUE
FIGURE 67 W. L. GORE & ASSOCIATES, INC.: REGIONAL REVENUE
Interventional Cardiology Market
The Interventional Cardiology Market held a value of USD 15,130.75 Million in 2018 and Interventional Cardiology Market is expected to register a CAGR of 7.25% during the assessment period of 2019 to 2025.
$15,130.75 Million
Market Size
7.25%
CAGR
Asia Pacific
Dominating Region
2020-2027
Forecast Period
Segmentation
Key Players
- ABIOMED (US)
- Abbott (US)
- ACIST Medical Systems Inc. (US)
- Braun Melsungen AG (Germany)
- BD (US)
- Biosense Webster Inc (US)
- Biotronik SE & Co. KG (Germany)
- Boston Scientific Corporation (US)
- Cardinal Health (US)
- Cook Medical (US)
- Edwards Lifesciences Corporation (US)
- GE Healthcare (US).
Drivers
- Favorable reimbursement scenario in developed countries
- Support by government organizations
- Increasing technological advancements
Interventional Cardiology Market Forecast
Interventional Cardiology Market held a value of USD 15,130.75 Million in 2018 and Interventional Cardiology Market is expected to register a CAGR of 7.25% during the assessment period of 2019 to 2025.
Interventional Cardiology Market Synopsis
Interventional cardiology deals with the catheter-based treatment of heart diseases. Scrutinizing all the global territories, it has been noticed that there is a huge rise in the number of cardiac diseases. This can be attributed to the change in lifestyle, leading to lifestyle diseases. Each year cardiovascular diseases cause 3.9 million deaths in Europe and over 1.8 million deaths in the European Union (EU).
In addition to that, the rise in the number of clinical trials of devices for use in interventional cardiology procedures is set to propel the growth of the market. For instance, in August 2018, B. Braun Melsungen AG announced that its drug-coated balloon ‘SeQuent Please’ for percutaneous transluminal coronary angioplasty showed positive results in the BASKET-SMALL 2 clinical trial. Moreover, the trend of bioresorbable stents going to contribute substantially to the growth of the market. For instance, in February 2019, Biotronik was granted approval from the FDA for its a drug-eluting stent system which is ultrathin and bioabsorbable for the treatment of patients with coronary artery disease.
Interventional Cardiology Market Influencer
Increasing provision and backing provided by regulatory authorities to companies operating in the interventional cardiology market, as well as the patients, act as a significant factor that pushes the growth of the Interventional cardiology market globally. Also, several prominent players are continuously involved in launching new and improved products in the market. Such initiatives also promise a massive level of growth in the Interventional cardiology market. In addition to that, the emergence of bioresorbable stents is catching the maximum attention of medical professionals due to its many benefits.
Interventional Cardiology Market Drivers
- Growing preference for minimally invasive procedures owing to less post-operative pain and speedy recovery
- Favorable reimbursement scenario in developed countries. In Germany, angioplasty with stenting using bare-metal stents is reimbursed solely via the diagnosis-related group (DRG).
- Support by government organizations. In February 2017, the National Pharmaceuticals Pricing Authority (NPPA), India’s drug pricing regulator, brought down the prices of stents by 85% in India.
- Rise in the incidence rates of cardiac diseases in developing as well as developed countries
- Partnerships and collaborations between key players and local players
- Increasing technological advancements and incorporation of innovation in the cardiac intervention industry
- High investment in research and development
- Growing awareness created by medical professionals and key players about the benefits of interventional cardiology procedures, in comparison to open surgeries among the patients
Interventional Cardiology Market Restraints
- Product Recalls: In March 2017, Abbott Vascular recalled three products i.e., Abbott NC Trek RX Coronary Dilatation Catheter, Abbott NC Traveler Coronary Dilatation Catheter, and Abbott NC Tenku RX PTCA Balloon Catheter. The recall was carried out as there were 19 reports of injury, and one report of a death associated with difficulty in removing the protective balloon sheath in case of these three products.
- Risk of bloodstream infections in patients can reduce the preference rate
Interventional Cardiology Market Segmentation
Interventional Cardiology Market By Product Type
- Stents: The stents segment is further segmented into drug-eluting stents, bare-metal stents, and bioresorbable vascular scaffolds. The stents segment held the largest share in 2018 due to a number of product launches by key companies such as Medtronic, Boston Scientific Corporation, and others.
- PTCA Catheters: This segment has been further divided into balloon catheters and guiding catheters. The PTCA catheters segment is expected to be the fastest-growing during the forecast period. The increase in rates of catheter induction in developing countries is likely to boost the growth of the market. Also, rising product launches by key players significantly contribute to the growth of the market. For instance, in June 2016, ASAHI INTECC Company Limited launched the ASAHI Caravel catheter in the US. This launch gave Caravel the lowest crossing profile of any of the purely braided microcatheters in the US. Such initiatives are expected to drive Interventional cardiology market growth.
- Plaque Modification Devices: The rising cases of atherectomy and thrombectomy cases worldwide is fueling the growth of this segment during the assessment period.
- Coronary Guidewires: The increasing use of guidewire technology acts as a major reason for the growth of this segment. Also, strategic initiatives by key players are also likely to drive Interventional cardiology market growth. For instance, in April 2018, ASAHI INTECC Company Limited announced the commencement of direct sales of its main product, PTCA guidewires in the US.
- Accessories: Accessories used in the interventional cardiology procedures include inflation devices, torquers, rotating hemostatic valves (Y-Connector), control syringes, manifold, extension lines, and others. The specificity and the necessity of accessories in the success of intervention procedures are likely to drive the segment growth.
Interventional Cardiology Market By End-User
- Hospitals: Hospitals held the majority share in 2018 owing to the high success rates of procedures conducted in a hospital. Approximately 200,000 cardiac arrests occur each year in hospitals, and 24 percent of those patients survive, whereas in less than six percent survive in an out-of-hospital cardiac arrest.
- Cardiac Catheterization Laboratories: This segment is anticipated to be the fastest growing during the forecast period owing to the increase in the number of cardiac intervention procedures conducted in these labs. The high uptake and adoption of patients and medical professionals towards the use of such labs boost the growth of this segment. For instance, more than one million diagnostic cardiac catheterizations (excluding percutaneous coronary
- intervention–only procedures) are performed each year in the nearly 2,000 cardiac catheterization laboratories in the US.
- Ambulatory Surgical Centers: With the increase in the number of cases for PCI procedures, the population is turning towards these centers for treatment due to reduced turnaround time. This factor is driving the growth of this segment.
- Others: Others include research firms, academic organizations, and simulation centers.
Interventional Cardiology Market By Region
- Americas: Americas was the largest regional market in 2018, owing to the increased cases of coronary diseases in this region. Percutaneous coronary intervention is one of the two most common procedures performed on patients with coronary artery disease in the US. For instance, a Percutaneous coronary intervention procedure is performed on 600,000 patients annually in the US and has the highest aggregate cost of all cardiovascular procedures. Also, the presence of major players, such as Boston Scientific Corporation, GE Healthcare, and Cardinal Health.
- Europe: The European region holds the second largest share owing to an increased number of hospitalizations for techniques such as carotid artery angioplasty and cerebral angioplasty.
- Asia-Pacific: The Asia-Pacific region is predicted to be the fastest-growing region in the global interventional cardiology market. Robust marketing initiatives by the manufacturers to consumers are playing a substantial role in increasing the target audience and thus increasing the Interventional cardiology market size in this region. Also, the increase in the setups of research and development centers, along with the rise in the number of partnerships and collaborations, is driving the growth of this region.
- Middle East & Africa: This region holds the least share but is expected to increase in the coming years due to the focus of key companies on such untapped regions.
Interventional Cardiology Market Key Players
- ABIOMED (US)
- Abbott (US)
- ACIST Medical Systems, Inc. (US)
- Braun Melsungen AG (Germany)
- BD (US)
- Biosense Webster, Inc (US)
- Biotronik SE & Co. KG (Germany)
- Boston Scientific Corporation (US)
- Cardinal Health (US)
- Cook Medical (US)
- Edwards Lifesciences Corporation (US)
- GE Healthcare (US)
- Koninklijke Philips N.V. (Netherlands)
- Life Vascular Devices Biotech S.L. (Spain)
- Medtronic (Ireland)
- Merit Medical Systems, Inc (US)
- Terumo Corporation (Japan)
- L. Gore & Associates, Inc. (US)
Report Scope:
| Report Attribute/Metric | Details |
|---|---|
| Market Size | 2018: 15,130.75 Million |
| CAGR | 7.25% (2019-2025) |
| Base Year | 2019 |
| Forecast Period | 2020-2027 |
| Historical Data | 2018 |
| Forecast Units | Value (USD Million) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors and Trends |
| Segments Covered | Type, End-User and Region |
| Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
| Key Vendors | ABIOMED (US), Abbott (US), ACIST Medical Systems, Inc. (US), Braun Melsungen AG (Germany), BD (US), Biosense Webster, Inc (US), Biotronik SE & Co. KG (Germany), Boston Scientific Corporation (US),Cardinal Health (US), Cook Medical (US), Edwards Lifesciences Corporation (US), GE Healthcare (US), Koninklijke Philips N.V. (Netherlands), Life Vascular Devices Biotech S.L. (Spain), Medtronic (Ireland), Merit Medical Systems, Inc (US), Terumo Corporation (Japan), L. Gore & Associates, Inc. (US) |
| Key Market Opportunities |
|
| Key Market Drivers |
|
Frequently Asked Questions (FAQ) :
Interventional cardiology market is expected to grow substantially from its last recorded value of 15.13 billion by 2025.
Interventional cardiology market is projected to register a moderate 7.25% CAGR in the forecast period (2019-2025).
The stents segment is expected to observe substantial demand over the review period.
The hospital segment is slated to expand as the fastest-growing segment.
A few eminent market players operating in the global interventional cardiology market are GE Healthcare (US), Koninklijke Philips N.V. (Netherlands), Medtronic (Ireland), among others.
